Fluciclovine PET/CT in Multiple Myeloma Patients

Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients

Recruiting

Interested in participating?

Key information

Conditions

Myeloma, Multiple Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell PET-CT Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Oslo University Hosptal

Oslo, 0424, Norway

Location status: Recruiting

Location contact

Mona-Elisabeth Revheim, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Multiple myeloma patients suitable for ASCT treatment

Exclusion criteria

Patients with contraindications to ASCT treatment

Treatment and study plan

Primary outcomes

Comparing of image findings at PET

Time frame: 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Mona-Elisabeth Revheim, MD, PhD, MHA

CONTACT

[email protected]

+4790659373

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Registry information

Official study title

PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose

Acronym: FLUCIPET

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2029
First posted: May 29, 2019
Registry last updated: May 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting